Search the Newsreel

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Bristol Myers Squibb and Bain Capital are establishing a new biopharmaceutical company focused on developing therapies for autoimmune diseases. The venture will be launched with $300 million in financing, primarily led by Bain Capital and including funds from the Canada Pension Plan Investment Board. …

Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma

Bristol Myers Squibb's stock (BMY) rose 5.5% after the FDA accepted its New Drug Application for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, supported by positive Phase 3 data. This development is crucial for BMS as it aims to strengthen its …

Bristol-Myers Squibb Company (BMY) Q2 2024 earnings summary

Bristol-Myers Squibb (BMY) reported strong Q2 2024 results with revenues up 9% to $12.2B, driven by its Growth Portfolio, despite Revlimid declines. The company achieved several regulatory approvals and completed major acquisitions, expanding its pipeline. BMY also launched a $1.5B cost-saving initiative and raised …

Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Bristol-Myers Squibb (BMY) aims for sustained top-tier growth by focusing on transformational medicines, operational excellence, and disciplined capital allocation, having achieved double-digit revenue growth in 2024. The company highlights five key growth products and anticipates next-wave assets like the CELMoD platform and Milvexian to …

MYE stock trades steady as Myers Industries focuses on margin and growth after 2024 earnings beat

Myers Industries Inc. (MYE) stock is trading steadily after beating 2024 earnings expectations and providing solid 2025 guidance. The company, a US plastics and materials handling specialist, is emphasizing margin protection, cost discipline, and cash flow generation, which supports its regular dividend. Investors are …

Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run?

Bristol-Myers Squibb (BMY) has seen a 31.9% return in the past year, leading to a mixed valuation picture. While the stock screens as undervalued on some market-based checks, with a fair P/E ratio of 19.2x compared to its current 17.0x, concerns about patent expirations …

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day

Bristol Myers Squibb Co. (BMY) stock advanced 3.05% to $60.51 on Thursday, outperforming the broader market which saw the S&P 500 Index fall 0.51% and the Dow Jones Industrial Average fall 0.20%. This marks the stock's second consecutive day of gains despite an overall …

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled

Bristol-Myers Squibb Co (BMY) stock rose 3.12% on July 15, driven by positive late-stage clinical trial results, increased institutional inflows into the defensive pharmaceutical sector, and favorable technical indicators. Despite facing patent expirations and pricing negotiation risks, the company's diversification strategy and pipeline successes …

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers Squibb (BMY) has seen a 1.8% return over the past month, slightly outperforming the S&P 500 composite. The company's earnings estimates have been revised upwards, with a Zacks Rank #3 (Hold), and it reported strong revenue and EPS beats in the last …

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers Squibb (BMY), a biopharmaceutical company within the Zacks Medical - Biomedical and Genetics industry, has a strong track record of surpassing earnings estimates in its last two reports, with an average surprise of 9.64%. With recent estimates moving higher and a positive …

KALEKIM KIMYEVI - KAP Haberleri - 2026-07-09 tarihli

KALEKIM KIMYEVI - KAP Haberleri - 2026-06-16 tarihli

Mastermyne Group (ASX:MYE) Surges on FY26 Earnings Upgrade and Encouraging Order Book

Pharma-Dividenden als Rentenbaustein: Bristol-Myers Squibb, Novo Nordisk und Merck

This Myers Industries, Inc. (NYSE:MYE) Analyst Is Way More Bearish Than They Used To Be

One Analyst Just Shaved Their Myers Industries, Inc. (NYSE:MYE) Forecasts Dramatically

Bristol-Myers Squibb übertrifft im ersten Quartal 2026 die Gewinn- und Umsatzerwartungen

Bristol-Myers Squibb Aktie: FDA-Durchbruch

Myeco Group Ltd (ASX:MCO) Shares Fly 29% But Investors Aren't Buying For Growth

Insights: MyEco Group Ltd (ASX:MCO)

Myer Holdings Limited's (ASX:MYR) largest shareholders are individual investors who were rewarded as market cap surged AU$112m last week

Bristol Myers Squibb: Prognose erhöht, KGV 7 – ist die Aktie jetzt ein Kauf?

Bristol-Myers Squibb Aktie | US1101221083 | ETR:BRM | News & Aktienkurs | FRA:BRM

CASA-EMTIA-PETROL, CASA Şirket Bilgileri

MYECO Group Ltd (ASX:MCO)

BRISTOL-MYERS SQUIBB AKTIE | BRM | Aktienkurs | US1101221083 | News | 850501